- Home
- GF vs THTX Comparison
GF vs THTX Comparison
Compare GF & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- THTX
- Stock Information
- Founded
- GF 1990
- THTX 1993
- Country
- GF Germany
- THTX Canada
- Employees
- GF N/A
- THTX N/A
- Industry
- GF Investment Managers
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- THTX Health Care
- Exchange
- GF Nasdaq
- THTX Nasdaq
- Market Cap
- GF 155.4M
- THTX 144.8M
- IPO Year
- GF N/A
- THTX N/A
- Fundamental
- Price
- GF $11.97
- THTX $3.20
- Analyst Decision
- GF
- THTX Hold
- Analyst Count
- GF 0
- THTX 1
- Target Price
- GF N/A
- THTX N/A
- AVG Volume (30 Days)
- GF 28.1K
- THTX 260.8K
- Earning Date
- GF 01-01-0001
- THTX 07-09-2025
- Dividend Yield
- GF 0.82%
- THTX N/A
- EPS Growth
- GF N/A
- THTX N/A
- EPS
- GF N/A
- THTX N/A
- Revenue
- GF N/A
- THTX $84,378,000.00
- Revenue This Year
- GF N/A
- THTX N/A
- Revenue Next Year
- GF N/A
- THTX $13.76
- P/E Ratio
- GF N/A
- THTX N/A
- Revenue Growth
- GF N/A
- THTX 2.19
- 52 Week Low
- GF $7.38
- THTX $1.12
- 52 Week High
- GF $9.41
- THTX $3.22
- Technical
- Relative Strength Index (RSI)
- GF 54.35
- THTX 71.13
- Support Level
- GF $11.39
- THTX $2.28
- Resistance Level
- GF $12.29
- THTX $3.22
- Average True Range (ATR)
- GF 0.22
- THTX 0.02
- MACD
- GF -0.02
- THTX -0.02
- Stochastic Oscillator
- GF 40.29
- THTX 68.75
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.